Clinical Trials Arena April 11, 2024
The TELE-ACS designed to test SHL Telemedicine’s SmartHeart system was also able to significant drop emergency hospital visits by 41%.
Israel-based SHL Telemedicine has announced that a UK clinical study of its SmartHeart system aimed at monitoring patients recovering from acute coronary syndrome (ACS) saw a 76% drop in hospital readmissions.
The study, carried out by Imperial College London and dubbed TELE-ACS, also saw a 41% drop in the likelihood of patients monitored by the technology vising an emergency department and decreases in patient-reported symptoms, including chest pain, breathlessness, and dizziness.
The SmartHeart system is a wearable 12-lead electrocardiogram (ECG) designed to monitor and manage post-ACS patients by reducing hospital readmissions and unplanned coronary revascularisations by relaying patient symptoms and...
Today's Sponsors
Today's Sponsor